Community/Retail

The Magic of Midyear

By

In this clip, Erin McCreary, PharmD, BCPS, an antimicrobial stewardship/infectious disease clinical pharmacist at the University of Pittsburgh Medical Center, reflects on her experience of returning to Anaheim for ASHP Midyear 4 years after doing so as a student.

The 2018 ASHP Midyear Clinical Meeting got off to a magical start today when basketball legend, businessman, and HIV/AIDS advocate Earvin “Magic” Johnson delivered the keynote address at the convention’s opening session, drawing upon his experiences, both on the basketball court and in the business world, to empower attendees to embrace their potential as health care providers and leaders.

In this clip, Mark Eastham, RPh, the senior vice president and general manager of McKesson RxO, discusses recent trends in health care delivery.

Brock Slabach, MPH, FACHE, Senior Vice-President of the National Rural Health Association, discussed new developments in rural health care at the American Society of Health-System Pharmacists (ASHP) Midyear 2018 Clinical Meeting in Anahein, CA. In this clip, he discusses how Congress might support rural health care in 2019.

The American Society of Health-Systems Pharmacists 2018 Midyear Clinical Meeting is right around the corner, and Pharmacy Times will be on site in Anaheim, CA to cover the conference.

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine/Valsartan combination tablets and Amlodipine Valsartan/Hydrochlorothiazide combination tablets, due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.

The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have an NTRKgene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.